Fig. 3From: Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetesTreatment effect. The figure displays the treatment effect (β-coefficient and SE) of vildagliptin (treating glibenclamide as reference group) on EPC number (a) and SDF-1α levels (b) in repeated measure GLM models after adjustment for baseline values. (*p < 0.05; **p < 0.01)Back to article page